Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2010 - 2026)

Emergent BioSolutions' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $23.5 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 7.48% year-over-year to $23.5 million in Q1 2026; TTM through Mar 2026 was $93.9 million, a 11.67% decrease from a year earlier, with the FY2025 full-year figure at $95.8 million, down 11.95% from the prior year.
• Depreciation & Amortization (CF) steadied at $23.5 million in Q1 2026 per EBS's latest filing, from $23.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $44.5 million in Q2 2022 and bottomed at $23.4 million in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $28.0 million (2023), against an average of $29.2 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 34.04% in 2022 and decreased 26.07% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $35.7 million in 2022, then decreased by 17.09% to $29.6 million in 2023, then decreased by 12.16% to $26.0 million in 2024, then decreased by 9.62% to $23.5 million in 2025, then changed by 0.0% to $23.5 million in 2026.
• Per Business Quant, the three latest EBS Depreciation & Amortization (CF) figures stand at $23.5 million (Q1 2026), $23.5 million (Q4 2025), and $23.4 million (Q3 2025).